Emerg Infect Dis. 2024 Nov;30(11):2352-2361. doi: 10.3201/eid3011.240043.
We studied SARS-CoV-2 binding and neutralizing antibody titers among previously infected persons in the United States over time. We assayed SARS-CoV-2 spike protein receptor-binding domain and neutralizing antibody titers for a convenience sample of residual clinical serum specimens that had evidence of prior SARS-CoV-2 infection gathered during January 2021-February 2022. We correlated titers and examined them by age group (<18, 18-49, 50-64, and >65 years) across 4 different SARS-CoV-2 variant epochs. Among selected specimens, 30,967 had binding antibody titers and 744 had neutralizing titers available. Titers in specimens from children and adults correlated. In addition, mean binding antibody titers increased over time for all age groups, and mean neutralization titers increased over time for persons 16-49 and >65 years of age. Incorporating binding and neutralization antibody titers into infectious disease surveillance could provide a clearer picture of overall immunity and help target vaccination campaigns.
我们研究了美国既往感染者体内的 SARS-CoV-2 结合抗体和中和抗体效价随时间的变化情况。我们检测了 SARS-CoV-2 刺突蛋白受体结合域和中和抗体效价,所用的是方便抽样的 2021 年 1 月至 2022 年 2 月期间收集的、具有既往 SARS-CoV-2 感染证据的临床剩余血清标本。我们对效价进行了相关性分析,并按年龄组(<18 岁、18-49 岁、50-64 岁和>65 岁)和 4 个不同的 SARS-CoV-2 变异时期进行了检查。在所选择的标本中,有 30967 份具有结合抗体效价,744 份具有中和效价。儿童和成人标本的效价具有相关性。此外,所有年龄组的结合抗体效价随时间推移而增加,16-49 岁和>65 岁人群的中和抗体效价随时间推移而增加。将结合抗体和中和抗体效价纳入传染病监测中,可以更清楚地了解整体免疫情况,并有助于有针对性地开展疫苗接种活动。